Mutations in IDH1 and IDH2 result in a gain-of-function that converts alpha-ketoglutarate to 2-HG. Elevated levels of 2-HG interfere with cellular differentiation and DNA methylation, contributing to oncogenesis. By inhibiting these mutant enzymes, IDH inhibitors aim to reduce 2-HG levels, thereby restoring normal cellular function and differentiation.
